Market News / Story
Bayer Aktiengesellschaft (BAYN) FDA Accepts sNDA for Kerendia in CKD Without Diabetes
·
Bayer said the FDA accepted its supplemental NDA for Kerendia (finerenone) to treat adults with chronic kidney disease without diabetes, based on the Phase III FIND-CKD trial. Material Details #DetailAI Analyst View1FDA accepts sNDA for KerendiaRegulatory step that could expand Kerendia’s label, opening a new CKD population and potential revenue stream.2Indication: CKD without diabetesTargets a large unmet group; up to ~70% of CKD patients are non-diabetic, expanding…